title: Respiratory syncytial virus infection: from biology to therapy: a perspective.
abstract: Respiratory syncytial virus (RSV) is responsible for significant morbidity and mortality, particularly in infants younger than 18 months and in the elderly. To date, there are few effective treatment options available to prevent or treat RSV infections. Attractive therapeutic strategies include targeting host epithelial adhesion molecules required for RSV infection, enhancing localized cell-mediated immunity, interfering with RSV viral gene expression and developing a multigene DNA vaccine. The most recent data supporting the advantages and limitations of each of these approaches are discussed in detail. Several promising strategies offer hope for safe and effective prophylaxis and treatment of RSV infection.
authors.affiliation: From the *Joy McCann Culverhouse Airway Disease Research Center, Department of Internal Medicine, University of South Florida College of Medicine; and the †James A. Haley VA Medical Center, Tampa, FL.
authors.forename: Shyam S
authors.initials: SS
authors.lastname: Mohapatra
authors.forename: Richard F
authors.initials: RF
authors.lastname: Lockey